Dirk Brehmer Email and Phone Number
Dirk Brehmer work email
- Valid
- Valid
- Valid
Dirk Brehmer personal email
Driving Global Developing Pipeline Strategy and External Innovation in Gastroenterology, Hepatology and OncologyAs an experienced pharmaceutical leader with over 23 years of expertise in gastroenterology, hepatology, and oncology, I am confident in my ability to drive global scientific innovation and partnering at Dr. Falk Pharma. My role is essential in developing and executing scientific and commercial strategies for the global pipeline. I evaluate new opportunities, lead licensing deals, and manage external alliances. My ultimate goal is to provide high-quality and patient-centric solutions for unmet medical needs, drawing on my broad knowledge of drug discovery, development, and translational research. My strong commercial awareness and entrepreneurial approach, coupled with my range of perspectives and experiences from working in various therapeutic areas, regions, and organizations, allow me to cultivate strong relationships with key opinion leaders, academic institutions, biotech companies, and contract research organizations.As a member of the senior leadership team, I am dedicated to contributing to the overall vision and direction of the company while supporting the development and growth of my team members. I am confident in my ability to deliver results and drive innovation in the fields of gastroenterology, hepatology, and oncology.
Dr. Falk Pharma
View- Website:
- drfalkpharma.de
- Employees:
- 336
-
Head Of Global External Innovation And Business Development And Science, Strategy, Bd And LDr. Falk PharmaFreiburg, Bw, De
-
Scientific AdvisorNeosphere Biotechnologies Gmbh Dec 2023 - Present -
Head Of Global External Innovation And Business Development / Science, Strategy, Bd&LDr. Falk Pharma Nov 2022 - PresentFreiburg Im Breisgau, Baden-Württemberg, De- Strategy (Science & Commercials)- Global Search: pre-clinical, Ph1-3, and commercialized products- Global BD, In & Out-licensing, M&A- Alliance Management - Deep scientific evaluations - Market Research - Strategic Pipelinemanagement- SLT member
-
Head Of External Innovation And Business Development / Science, Strategy, Bd&LDr. Falk Pharma Jul 2020 - Nov 2022Freiburg Im Breisgau, Baden-Württemberg, DeHave built the global infrastructure for external innovation including the implementation of innovation champions as part of the established stronghold concept. Built the road map for global and active scouting, scientific and commercial due diligence, BD and licensing as well as alliance management.
-
External Innovation Champion Oncology, EuropeJohnson & Johnson Innovative Medicine Jul 2019 - Jul 2020External innovation and partnering role as an expansion of my responsibility as Scientific Director and Group Leader for Pre-Clinical Research and Early Clinical Development. Opportunities Scouting, Due Diligence, and Alliance Management for Oncology -
Scientific DirectorJohnson & Johnson Innovative Medicine Oct 2016 - Jul 2020Oncology therapeutic area; globally acting group leader for the discovery and development of small and large molecule inhibitors (pre-clinic/Ph1) at Janssen Pharmaceutica, a division of Johnson & Johnson in Beerse, BelgiumBuilt an innovative preclinical program pipeline engine applying diverse treatment modalities as well as different biological concepts to fuel the early clinical development pipeline against solid tumors. Several programs reached NME status and are tested in the clinic e.g. JNJ-64619178 best in class PRMT5i (Onametostat); JNJ-78306358 is a first-in-class HLA-G and CD3 bispecific antibody - Had the luxury of building and working with a highly dedicated team- Drug Discovery, Pharmacology, Translational Research & early Clinical Development- Small molecules (reversible and irreversible, degrader), antibodies (bispecifics, redirection, ADC, ADCC)- Built the foundation of the epigenetic platform at J&J by running several high-priority programs with different targets and modalities- Initiated and supported the J&J degrader concept for solid tumor targets- Johnson & Johnson Leadership Award eg for JNJ-64619178, a best-in-class PRMT5 inhibitor- Member of the Senior Leadership Team
-
Associate Scientific DirectorJohnson & Johnson Innovative Medicine Jul 2008 - Oct 2016Oncology therapeutic area, team leader for small and large molecule inhibitors at Janssen Pharmaceutica, a division of Johnson & Johnson in Beerse, Belgium.- From target identification to New-Molecular-Entity (NME): e.g.Erdafitinib (FGFRi), JNJ-38877605 (C-METi), and JNJ-26483327 (EGFRi). - Scientific grants application winner > 5M Euro from the Flemish Government for Science and Innovation. Built a European Academic Network to explore new small molecule concepts for targeting the conformational plasticity.- Scientific Liaison: MIT, Dundee and Edinburgh; Forma Therapeutics and Astex Therapeutics exploring several novel anti-cancer biology, targets and treatment modalities.
-
Co-Founding And Startup Member, Director Of Chemical Biology And Project ManagementKinaxo Biotechnologies --> Successfully Acquired By Evotec Dec 2006 - Jul 2008Co-founding/ Start-Up member of Kinaxo Biotechnology, an innovative and internationally leading company in the field of chemical proteomics & phospho-proteomics for compound profiling and identification of bio- and diagnostic maker(s). Group Leader for chemical biology/ proteomics/ kinase drug discovery and client/ project management.
-
Research Investigator IiGpc Biotech Mar 2005 - Dec 2006Martinsried, DeLab/ Project lead for novel type II kinase inhibitors (hit-ID to lead optimization). Initiated a type-II kinase fragment library based on chemical proteomics that led to the scientific foundation of Proteros Fragments GmbH. -
Scientist IAxxima Pharmaceutical Dec 2002 - Mar 2005Kinase drug discovery and chemical proteomics
-
Postdoctoral ResearcherUniversity Of Heidelberg, Zmbh Dec 2001 - Dec 2002Heidelberg, DeExploration of chaperone-assisted protein folding as a basic for general drug discovery targeting the conformational plasticity in a disease content - Protein purification and folding- Biophysical analyses of ligand-protein and protein-protein interactions- Enzyme kinetics- Molecular biology -
Phd StudentAlbert-Ludwigs-Universität Freiburg Im Breisgau Sep 1998 - Dec 2001Freiburg, Baden-Württemberg, DeMolecular Chaperones, Prof. Bernd BukauNominated for best PhD thesis in 2000/2001
Dirk Brehmer Skills
Dirk Brehmer Education Details
-
The University Of FreiburgChemistry & Biochemistry
Frequently Asked Questions about Dirk Brehmer
What company does Dirk Brehmer work for?
Dirk Brehmer works for Dr. Falk Pharma
What is Dirk Brehmer's role at the current company?
Dirk Brehmer's current role is Head of Global External Innovation and Business Development and Science, Strategy, BD and L.
What is Dirk Brehmer's email address?
Dirk Brehmer's email address is di****@****mail.de
What schools did Dirk Brehmer attend?
Dirk Brehmer attended The University Of Freiburg.
What skills is Dirk Brehmer known for?
Dirk Brehmer has skills like Oncology, Protein Kinases, Drug Discovery, Signal Transduction, Pharmaceutical Industry, Drug Design, Chemical Biology, Epigenetics, Proteomics, International Project Management, Cell Biology, Pharmacology.
Who are Dirk Brehmer's colleagues?
Dirk Brehmer's colleagues are Anil Cirganis, Ilona Buck, Marie Benders, Alexandra Kukla, Edda Müller, Silke Meszaros, Phd, Yi-An (Ann) Chen.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial